Meeting
2019 ASCO Annual Meeting
Brigatinib in pretreated patients with ALK-positive advanced NSCLC.
Authors
Renaud Descourt
CHU Morvan, Brest, France
Renaud Descourt , Maurice Perol , Gaelle Rousseau-Bussac , David Planchard , Bertrand Mennecier , Marie Wislez , Alexis B. Cortot , Florian Guisier , Radj Gervais , Loick Galland , Roland Schott , Eric Dansin , Jennifer ARRONDEAU , Jean-Bernard Auliac , Christos Chouaid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9045)
DOI
10.1200/JCO.2019.37.15_suppl.9045
Abstract #
9045
Poster Bd #
368
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).
First Author: Vineeth Tatineni
Poster
2023 ASCO Annual Meeting
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.
First Author: D. Ross Camidge
Poster
2022 ASCO Annual Meeting
Crizotinib in ROS1-rearranged lung cancer (EUCROSS): Updated overall survival.
First Author: Sebastian Yves Friedrich Michels
Poster
2020 ASCO Virtual Scientific Program
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
First Author: D. Ross Camidge